Clinical Trials · NCT06552598
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Tongji Hospital
- Enrollment
- 97
- Start date
- Apr 2024
- Locations
- 1 site, China
- Primary endpoint
- SAEs and AEs in Phase I